Published in Clin Vaccine Immunol on September 01, 2006
Expanding roles for CD4⁺ T cells in immunity to viruses. Nat Rev Immunol (2012) 2.94
Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine (2008) 1.54
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol (2010) 1.42
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses (2008) 1.33
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine (2009) 1.15
A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol (2012) 1.12
A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine (2011) 1.12
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One (2011) 1.05
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One (2011) 1.05
Novel vaccines against influenza viruses. Virus Res (2011) 1.04
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) (2014) 1.01
A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir Viruses (2009) 1.01
Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2011) 0.99
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One (2011) 0.98
Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol (2010) 0.98
RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses (2010) 0.97
Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine (2009) 0.96
Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One (2012) 0.96
Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol (2007) 0.95
Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther (2014) 0.95
Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J (2010) 0.94
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Multipronged CD4(+) T-cell effector and memory responses cooperate to provide potent immunity against respiratory virus. Immunol Rev (2013) 0.93
Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. J Proteome Res (2011) 0.91
Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol (2010) 0.90
DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther (2012) 0.87
Intake of korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza a virus. J Ginseng Res (2012) 0.85
Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol (2012) 0.85
Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine (2012) 0.84
Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. Vaccine (2011) 0.84
Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies. PLoS One (2013) 0.83
How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines (2009) 0.83
Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One (2013) 0.83
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (Lond) (2013) 0.83
Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. Virol J (2009) 0.82
Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother (2014) 0.82
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2012) 0.82
Near-infrared laser adjuvant for influenza vaccine. PLoS One (2013) 0.81
Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine. Pharm Res (2014) 0.81
Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice. PLoS One (2012) 0.81
Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine (2014) 0.81
Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays. Influenza Other Respir Viruses (2011) 0.80
Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology (2011) 0.80
An interspecific Nicotiana hybrid as a useful and cost-effective platform for production of animal vaccines. PLoS One (2012) 0.79
Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens. Clin Vaccine Immunol (2011) 0.79
Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine (2011) 0.79
Protective neutralizing influenza antibody response in the absence of T follicular helper cells. Nat Immunol (2016) 0.79
Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses. J Virol (2014) 0.77
Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection. Vaccine (2014) 0.76
Nasal mucosa derived-mesenchymal stem cells from mice reduce inflammation via modulating immune responses. PLoS One (2015) 0.76
Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen. Nano Life (2014) 0.76
Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection. PLoS One (2013) 0.76
Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One (2013) 0.76
A direct and nonredundant role for thymic stromal lymphopoietin on antiviral CD8 T cell responses in the respiratory mucosa. J Immunol (2014) 0.76
Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4. Int J Mol Sci (2015) 0.76
Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin. Virol J (2012) 0.76
Evaluation of multivalent H2 influenza pandemic vaccines in mice. Vaccine (2017) 0.75
Modulation of gut microbiota and delayed immunosenescence as a result of syringaresinol consumption in middle-aged mice. Sci Rep (2016) 0.75
Rickettsia rickettsii outer membrane protein YbgF induces protective immunity in C3H/HeN mice. Hum Vaccin Immunother (2015) 0.75
Serological evidence for influenza virus infection in Korean wild boars. J Vet Med Sci (2014) 0.75
Lysosome-associated membrane glycoprotein (LAMP)--preliminary study on a hidden antigen target for vaccination against schistosomiasis. Sci Rep (2015) 0.75
Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model. Sci Rep (2016) 0.75
Yeast Surface-Displayed H5N1 Avian Influenza Vaccines. J Immunol Res (2016) 0.75
Progress in developing virus-like particle influenza vaccines. Expert Rev Vaccines (2016) 0.75
Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses. PLoS One (2015) 0.75
Bone marrow-derived mesenchymal stem cells reduce immune reaction in a mouse model of allergic rhinitis. Am J Transl Res (2016) 0.75
Humoral immune responses during asthma and influenza co-morbidity in mice. Immunobiology (2017) 0.75
Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice. Vaccine (2017) 0.75
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. Front Immunol (2017) 0.75
Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides. Virology (Auckl) (2017) 0.75
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (1987) 13.03
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 9.73
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
Are we ready for pandemic influenza? Science (2003) 7.20
Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature (1978) 6.59
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med (1984) 6.27
A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol (1999) 6.03
Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol (1968) 5.69
Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J Exp Med (1975) 5.19
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine (2002) 4.45
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 3.62
Hepatic T cells and liver tolerance. Nat Rev Immunol (2003) 3.51
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
The antiviral activity of antibodies in vitro and in vivo. Adv Immunol (2001) 3.29
Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev (1997) 3.20
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis (2005) 3.20
Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell. Nature (1982) 3.17
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med (1977) 2.98
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med (1987) 2.81
Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol (1997) 2.69
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol (2000) 2.67
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol (2001) 2.47
DNA vaccines: progress and challenges. J Immunol (2005) 2.34
The IgG Fc receptor family. Ann Hematol (1998) 2.28
Advances in vaccine adjuvants. Nat Biotechnol (1999) 2.18
Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol (1981) 2.11
Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 2.09
Prominent usage of V beta 8.3 T cells in the H-2Db-restricted response to an influenza A virus nucleoprotein epitope. J Immunol (1993) 2.07
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine (2003) 2.04
Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines. J Immunol (1990) 1.95
CD1d-restricted NKT cells: an interstrain comparison. J Immunol (2001) 1.88
Virally induced modulation of murine IgG antibody subclasses. J Exp Med (1988) 1.79
Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med (1985) 1.77
Cytotoxic T lymphocytes produce immune interferon in response to antigen or mitogen. J Exp Med (1982) 1.76
Class I major histocompatibility complex-restricted cytolytic T lymphocytes recognize a limited number of sites on the influenza hemagglutinin. Proc Natl Acad Sci U S A (1989) 1.68
Rapid-response vaccines--does DNA offer a solution? Nat Biotechnol (2005) 1.67
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol (1997) 1.65
DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol (1999) 1.57
Preventing and treating influenza. BMJ (2003) 1.57
Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol (2002) 1.52
Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis (1999) 1.41
Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis (1999) 1.39
Quantitative relationships between an influenza virus and neutralizing antibody. Virology (1987) 1.37
Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol (2005) 1.28
Passive and active mechanisms trap activated CD8+ T cells in the liver. J Immunol (2004) 1.27
Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology (2003) 1.24
Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol (1995) 1.19
Contribution of T cell receptor affinity to overall avidity for virus-specific CD8+ T cell responses. Proc Natl Acad Sci U S A (2005) 1.16
Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol (1997) 1.12
The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies. J Gen Virol (1989) 1.10
Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis (2004) 1.07
Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol (2006) 1.03
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine (1999) 1.03
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine (1996) 1.00
Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles. Infect Immun (2005) 0.99
Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci (2001) 0.96
DNA immunization of mice with a plasmid encoding Neisseria gonorrhea PorB protein by intramuscular injection and epidermal particle bombardment. Vaccine (2004) 0.96
A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine (1999) 0.93
Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect Immun (1999) 0.89
Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease. Vaccine (2003) 0.86
Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol Res (2000) 0.84
Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Vaccine (1997) 0.79
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med (2015) 6.04
Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe (2007) 5.46
Targeted muscle reinnervation for real-time myoelectric control of multifunction artificial arms. JAMA (2009) 5.40
Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med (2015) 4.90
A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. Proc Natl Acad Sci U S A (2008) 3.99
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 3.70
Gain-of-function experiments on H7N9. Science (2013) 3.67
Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 3.62
Targeted reinnervation for enhanced prosthetic arm function in a woman with a proximal amputation: a case study. Lancet (2007) 3.54
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc Natl Acad Sci U S A (2009) 3.30
The influenza virus gene pool in a poultry market in South central china. Virology (2003) 3.25
Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol (2002) 2.97
Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. J Virol (2007) 2.89
Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS One (2008) 2.86
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J (2004) 2.53
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis (2005) 2.43
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission. J Virol (2010) 2.19
Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol (2010) 2.17
Quail carry sialic acid receptors compatible with binding of avian and human influenza viruses. Virology (2005) 2.17
Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B- and T-cell responses. J Gen Virol (2005) 2.15
Comparison of high-definition oscillometry -- a non-invasive technology for arterial blood pressure measurement -- with a direct invasive method using radio-telemetry in awake healthy cats. J Feline Med Surg (2013) 2.06
Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis (2010) 2.01
Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med (2007) 1.99
Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis (2009) 1.93
N-linked glycosylation attenuates H3N2 influenza viruses. J Virol (2007) 1.92
Paired analysis of TCRα and TCRβ chains at the single-cell level in mice. J Clin Invest (2010) 1.87
Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest (2007) 1.87
Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med (2004) 1.86
GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med (2011) 1.83
Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens. J Virol (2004) 1.83
Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol (2010) 1.81
Improved myoelectric prosthesis control accomplished using multiple nerve transfers. Plast Reconstr Surg (2006) 1.78
PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog (2010) 1.75
Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog (2010) 1.70
The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol (2013) 1.66
The crystal structure of aminoglycoside-3'-phosphotransferase-IIa, an enzyme responsible for antibiotic resistance. J Mol Biol (2003) 1.65
Replication and transmission of influenza viruses in Japanese quail. Virology (2003) 1.64
The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis. J Virol (2010) 1.63
Evidence of expanded host range and mammalian-associated genetic changes in a duck H9N2 influenza virus following adaptation in quail and chickens. PLoS One (2008) 1.63
Neurovirulence in mice of H5N1 influenza virus genotypes isolated from Hong Kong poultry in 2001. J Virol (2003) 1.62
Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to superinfection with Gram-positive respiratory pathogens. J Virol (2012) 1.57
Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis (2011) 1.56
Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine (2008) 1.54
T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci Transl Med (2012) 1.53
Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol (2009) 1.52
Bacterial sinusitis and otitis media following influenza virus infection in ferrets. Infect Immun (2006) 1.51
A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol (2007) 1.50
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis (2011) 1.49
Targeted reinnervation to improve prosthesis control in transhumeral amputees. A report of three cases. J Bone Joint Surg Am (2008) 1.48
Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics (2006) 1.45
Analysis of nondegradative protein ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin. Proc Natl Acad Sci U S A (2008) 1.42
Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol (2010) 1.38
Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol (2013) 1.34
An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. Proc Natl Acad Sci U S A (2006) 1.29
Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell responses. J Immunol (2007) 1.28
Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J Biol Chem (2005) 1.27
Avian influenza virus isolated in wild waterfowl in Argentina: evidence of a potentially unique phylogenetic lineage in South America. Virology (2008) 1.26
Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 1.26
Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology (2003) 1.24
Evidence of reassortment of pandemic H1N1 influenza virus in swine in Argentina: are we facing the expansion of potential epicenters of influenza emergence? Influenza Other Respir Viruses (2011) 1.21
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett (2005) 1.19
A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens. J Virol (2010) 1.18
Motivating factors for high rates of influenza vaccination among healthcare workers. Vaccine (2011) 1.18
Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal). J Vet Intern Med (2005) 1.17
The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J Biol Chem (2007) 1.17
Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog (2013) 1.16
Mutations in the NS1 C-terminal tail do not enhance replication or virulence of the 2009 pandemic H1N1 influenza A virus. J Gen Virol (2010) 1.16
Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol (2013) 1.15
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine (2009) 1.15
Characterization of influenza virus sialic acid receptors in minor poultry species. Virol J (2010) 1.13
Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis (2011) 1.12
Location rather than CD62L phenotype is critical in the early establishment of influenza-specific CD8+ T cell memory. Proc Natl Acad Sci U S A (2007) 1.10
Immunopathogenic and antibacterial effects of H3N2 influenza A virus PB1-F2 map to amino acid residues 62, 75, 79, and 82. J Virol (2011) 1.09
Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine (2005) 1.09
Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice. Am J Respir Crit Care Med (2010) 1.09
Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J Virol (2010) 1.09
Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol (2009) 1.08
Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One (2009) 1.08
A numerical study of the effects of bell pulsation dynamics and oral arms on the exchange currents generated by the upside-down jellyfish Cassiopea xamachana. J Exp Biol (2011) 1.08
Amino acid 316 of hemagglutinin and the neuraminidase stalk length influence virulence of H9N2 influenza virus in chickens and mice. J Virol (2012) 1.08
Evidence for avian H9N2 influenza virus infections among rural villagers in Cambodia. J Infect Public Health (2013) 1.08
The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother (2005) 1.07
Osteopathic medical education: renaissance or rhetoric? J Am Osteopath Assoc (2003) 1.07
Transmission studies resume for avian flu. Science (2013) 1.07
HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One (2010) 1.07
Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One (2011) 1.06
Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis (2006) 1.06
Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities. Clin Vaccine Immunol (2008) 1.05
Evidence for seasonal patterns in the relative abundance of avian influenza virus subtypes in blue-winged teal (Anas discors). J Wildl Dis (2014) 1.04
Outbreak of swine influenza in Argentina reveals a non-contemporary human H3N2 virus highly transmissible among pigs. J Gen Virol (2011) 1.04
Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell Signal (2009) 1.04
Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol (2011) 1.03
Influenza a viruses from wild birds in Guatemala belong to the North American lineage. PLoS One (2012) 1.02